Pasithea Therapeutics Updates Presentation Date at H.C. Wainwright Conference.

Pasithea Therapeutics Corp. announced a change in the date and time of its management presentation at the H.C. Wainwright 27th Annual Global Investment Conference. CEO Dr. Tiago Reis Marques will deliver a live company presentation on September 8 at 5:00 PM Eastern Time, with management available for one-on-one meetings throughout the event. The presentation will be webcast, and registration details are available. Pasithea is a clinical-stage biotechnology company focused on developing PAS-004, a next-generation macrocyclic MEK inhibitor.

Pasithea Therapeutics Corp. (NASDAQ: KTTA) has announced a change in the date and time of its management presentation at the H.C. Wainwright 27th Annual Global Investment Conference. CEO Dr. Tiago Reis Marques will now deliver a live company presentation on September 8 at 5:00 PM Eastern Time, with management available for one-on-one meetings throughout the event. The presentation will be webcast, and registration details are available.

Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839) and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).

The company's participation in the H.C. Wainwright conference provides an opportunity for investors and financial professionals to gain insights into the progress of PAS-004 and the company's overall strategic direction. The presentation and one-on-one meetings will offer a platform for stakeholders to engage with management and learn more about the company's pipeline and clinical trial results.

Pasithea Therapeutics Corp. [1]